Cargando…

TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension

BACKGROUND: Recently, some studies reported the pulmonary artery hypertension (PAH)–associated genes. However, a majority of patients with familial or sporadic PAH lack variants in the known pathogenic genes. In this study, we investigated the new causative gene variants associated with PAH. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Shinya, Yoshiki, Hiraide, Takahiro, Momoi, Mizuki, Goto, Shinichi, Suzuki, Hisato, Katsumata, Yoshinori, Kurebayashi, Yutaka, Endo, Jin, Sano, Motoaki, Fukuda, Keiichi, Kosaki, Kenjiro, Kataoka, Masaharu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174299/
https://www.ncbi.nlm.nih.gov/pubmed/33586470
http://dx.doi.org/10.1161/JAHA.120.019245
_version_ 1783702879274532864
author Shinya, Yoshiki
Hiraide, Takahiro
Momoi, Mizuki
Goto, Shinichi
Suzuki, Hisato
Katsumata, Yoshinori
Kurebayashi, Yutaka
Endo, Jin
Sano, Motoaki
Fukuda, Keiichi
Kosaki, Kenjiro
Kataoka, Masaharu
author_facet Shinya, Yoshiki
Hiraide, Takahiro
Momoi, Mizuki
Goto, Shinichi
Suzuki, Hisato
Katsumata, Yoshinori
Kurebayashi, Yutaka
Endo, Jin
Sano, Motoaki
Fukuda, Keiichi
Kosaki, Kenjiro
Kataoka, Masaharu
author_sort Shinya, Yoshiki
collection PubMed
description BACKGROUND: Recently, some studies reported the pulmonary artery hypertension (PAH)–associated genes. However, a majority of patients with familial or sporadic PAH lack variants in the known pathogenic genes. In this study, we investigated the new causative gene variants associated with PAH. METHODS AND RESULTS: Whole‐exome sequencing in 242 Japanese patients with familial or sporadic PAH identified a heterozygous substitution change involving c.226G>A (p.Gly76Ser) in tumor necrotic factor receptor superfamily 13B gene (TNFRSF13B) in 6 (2.5%) patients. TNFRSF13B controls the differentiation of B cell and secretion of inflammatory cytokines and may be involved in vascular inflammation. In silico structural analysis simulation demonstrated the structural instability of the N‐terminal region of the protein synthesized from TNFRSF13B p.Gly76Ser variant. These suggest that the TNFRSF13B p.Gly76Ser variant may be involved in the development of PAH via aberrant inflammation in pulmonary vessels. CONCLUSIONS: TNFRSF13B p.Gly76Ser variant is a candidate of novel causative gene variant for PAH.
format Online
Article
Text
id pubmed-8174299
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-81742992021-06-11 TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension Shinya, Yoshiki Hiraide, Takahiro Momoi, Mizuki Goto, Shinichi Suzuki, Hisato Katsumata, Yoshinori Kurebayashi, Yutaka Endo, Jin Sano, Motoaki Fukuda, Keiichi Kosaki, Kenjiro Kataoka, Masaharu J Am Heart Assoc Brief Communications BACKGROUND: Recently, some studies reported the pulmonary artery hypertension (PAH)–associated genes. However, a majority of patients with familial or sporadic PAH lack variants in the known pathogenic genes. In this study, we investigated the new causative gene variants associated with PAH. METHODS AND RESULTS: Whole‐exome sequencing in 242 Japanese patients with familial or sporadic PAH identified a heterozygous substitution change involving c.226G>A (p.Gly76Ser) in tumor necrotic factor receptor superfamily 13B gene (TNFRSF13B) in 6 (2.5%) patients. TNFRSF13B controls the differentiation of B cell and secretion of inflammatory cytokines and may be involved in vascular inflammation. In silico structural analysis simulation demonstrated the structural instability of the N‐terminal region of the protein synthesized from TNFRSF13B p.Gly76Ser variant. These suggest that the TNFRSF13B p.Gly76Ser variant may be involved in the development of PAH via aberrant inflammation in pulmonary vessels. CONCLUSIONS: TNFRSF13B p.Gly76Ser variant is a candidate of novel causative gene variant for PAH. John Wiley and Sons Inc. 2021-02-15 /pmc/articles/PMC8174299/ /pubmed/33586470 http://dx.doi.org/10.1161/JAHA.120.019245 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Brief Communications
Shinya, Yoshiki
Hiraide, Takahiro
Momoi, Mizuki
Goto, Shinichi
Suzuki, Hisato
Katsumata, Yoshinori
Kurebayashi, Yutaka
Endo, Jin
Sano, Motoaki
Fukuda, Keiichi
Kosaki, Kenjiro
Kataoka, Masaharu
TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title_full TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title_fullStr TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title_full_unstemmed TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title_short TNFRSF13B c.226G>A (p.Gly76Ser) as a Novel Causative Mutation for Pulmonary Arterial Hypertension
title_sort tnfrsf13b c.226g>a (p.gly76ser) as a novel causative mutation for pulmonary arterial hypertension
topic Brief Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8174299/
https://www.ncbi.nlm.nih.gov/pubmed/33586470
http://dx.doi.org/10.1161/JAHA.120.019245
work_keys_str_mv AT shinyayoshiki tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT hiraidetakahiro tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT momoimizuki tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT gotoshinichi tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT suzukihisato tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT katsumatayoshinori tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT kurebayashiyutaka tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT endojin tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT sanomotoaki tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT fukudakeiichi tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT kosakikenjiro tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension
AT kataokamasaharu tnfrsf13bc226gapgly76serasanovelcausativemutationforpulmonaryarterialhypertension